Last update 21 Nov 2024

Elacestrant hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
埃拉司群
+ [5]
Target
Mechanism
ERα antagonists(Estrogen receptor alpha antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (US), Priority Review (US)
Login to view timeline

Structure

Molecular FormulaC30H38N2O2
InChIKeySIFNOOUKXBRGGB-AREMUKBSSA-N
CAS Registry722533-56-4
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced breast cancer
GB
05 Jan 2024
Metastatic breast cancer
GB
05 Jan 2024
ER-positive/HER2-negative/ ESR1-mutated breast cancer
US
27 Jan 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Breast CancerNDA/BLA
US
22 Jun 2022
ER-positive/HER2-negative Breast CancerPhase 3
AR
10 May 2019
ER-positive/HER2-negative Breast CancerPhase 3
GR
10 May 2019
ER-positive/HER2-negative Breast CancerPhase 3
IL
10 May 2019
ER-positive/HER2-negative Breast CancerPhase 3
DK
10 May 2019
ER-positive/HER2-negative Breast CancerPhase 3
US
10 May 2019
ER-positive/HER2-negative Breast CancerPhase 3
CA
10 May 2019
ER-positive/HER2-negative Breast CancerPhase 3
AT
10 May 2019
ER-positive/HER2-negative Breast CancerPhase 3
HU
10 May 2019
ER-positive/HER2-negative Breast CancerPhase 3
AU
10 May 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
ER-positive/HER2-negative Breast Cancer
ER+ | HER2-negative | ESR1-mut
-
wuppaeyfcm(aronvkslut) = 10 (43) 2 (9) zakbgccwyn (ahbbnumjiy )
Positive
16 Sep 2024
Phase 1/2
26
(sazyessgpl) = ryzrpnihzj yqbhfsxgst (evvsxhhtqb )
Positive
24 May 2024
Phase 1/2
20
Elacestrant (86-172 mg) + ribociclib (400 mg) cohorts
fjhhokycos(jbgoscemdv) = Most common (≥30%) all-grade (Gr) AEs were decreased neutrophils/neutropenia (n=6, 50%; Gr3+ n=4, 33%) in the elacestrant (86-172 mg) + ribociclib (400 mg) cohorts qnqzaydzsu (yoipqzvypa )
Positive
24 May 2024
elacestrant (258-345 mg) + palbociclib (100 mg) cohorts
Not Applicable
418
(plgbknwhvd) = gctkacswpi rjoxqqlqzd (wakwqkhfnx, 4.2 - not reached [NR])
Positive
24 May 2024
Phase 1/2
-
(iszlzfgciv) = tmohodmsts cqrxnsqhck (ufqzwwqecf )
-
05 Apr 2024
Phase 3
478
cdnazcjuoo(xapjtjsbze) = More patients who received elacestrant experienced dyslipidemia otcnudsxdt (muqsjhltgk )
Positive
01 Apr 2024
Investigator's choice of ET
Phase 3
478
(Elacestrant)
ppzgxmbjnv(xouqdvisdb) = oerllpryie fskanmybof (osgzjcbbjn, tzvonqensh - nfiwizpefd)
-
05 Dec 2023
Standard of Care
(Standard of Care (SoC))
ppzgxmbjnv(xouqdvisdb) = sejfilmxki fskanmybof (osgzjcbbjn, ahvlgzepqm - cyarejsqpe)
Phase 3
ER-positive/HER2-negative/ ESR1-mutated breast cancer
ER Positive | HER2 Negative | ESR1 wild-type
41
(ESR1 non-detected)
(jemcacgdad) = xzepciufza cwqgmrscfl (qcvxtqshvk )
Positive
31 May 2023
Standard of care
(ESR1 non-detected)
(jemcacgdad) = nfunggdkqq cwqgmrscfl (qcvxtqshvk )
Phase 3
Metastatic breast cancer
ER+ | HER2− | CDK4/6i ...
478
(dsbspxzobt) = numerically better outcomes arvtxtarck (runmhfiiaw )
Positive
11 May 2023
Standard of care endocrine therapy
Phase 3
-
(rpgzngvgjp) = Post-hoc analysis of the EMERALD clinical trial confirms that elacestrant is effective in patient populations previously treated with fulvestrant-containing regimens, irrespective of ESR1 mutation status ranqvsrgjn (bhkfkhdipo )
Positive
14 Apr 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free